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Abstract The urokinase receptor (uPAR) is a receptor for both
urokinase plasminogen activator (uPA) and the adhesion protein
vitronectin. There are two forms of cell surface-bound uPAR;
intact uPAR and a cleaved form, uPAR(2+3), which is formed by
uPA-catalyzed cleavage of uPAR. In ligand-blotting experiments
we found that vitronectin binds uPAR but not uPAR(2+3). In
real-time biomolecular interaction analysis using recombinant,
soluble uPAR (suPAR) both plasma and multimeric forms of
vitronectin bound to intact, antibody-immobilized suPAR.
Monoclonal antibodies against domain 1 of uPAR blocked
suPAR binding to vitronectin and vitronectin did not interact
with suPAR(2+3). Both suPAR(2+3) and the isolated domain 1
failed to compete with the intact suPAR in binding to vitronectin.
We therefore conclude that the intact receptor is required for
efficient vitronectin binding.
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1. Introduction
Plasminogen activation catalyzed by the urokinase-type
plasminogen activator (uPA) is crucial for the proteolytic deg-
radation of the extracellular matrix and basement membrane
during tissue remodeling including cancer invasion [1,2]. A cell
surface receptor for uPA (uPAR) and type-1 plasminogen
activator inhibitor (PAI-1) play key roles as regulators of
this process, uPAR by enhancing cell surface plasmin gener-
ation and PAI-1 by inhibiting both receptor-bound uPA and
uPA in solution [3,4]. uPAR is a highly glycosylated protein
with a carboxy-terminal glycolipid membrane anchor [5,6].
The protein contains three homologous domains, each con-
sisting of approximately 90 amino acids and characterized by
a unique pattern of cysteine residues [7,8]. uPA binding is
mediated predominantly by the amino-terminal domain 1 of
uPAR [7], but the rest of the protein is also required for the
high a⁄nity binding [9,10]. Incubation with uPA or plasmin
results in the liberation of domain 1 from the remaining mem-
brane-bound part (designated uPAR(2+3)) of the receptor, as
demonstrated in a puri¢ed system as well as on the surface of
U937 histiocytic lymphoma cells [11,12]. Thus, uPA-catalyzed
cleavage of uPAR is a putative negative feedback regulation
mechanism for cell surface plasminogen activation [12].
In addition to uPA, binding of the multimeric form of the
adhesion protein vitronectin to uPAR has been demonstrated
on various cell types and puri¢ed systems [13^17] and uPAR-
mediated adhesion of vitronectin correlates with the forma-
tion of membrane complexes comprising integrins, caveolin
and uPAR itself [15]. The a⁄nity of vitronectin binding to
uPAR was reported to increase in the presence of pro-uPA,
whereas active PAI-1 totally abrogated the interaction
[14,16,17]. Based on some initial antibody competition studies
Wei and co-workers [13] proposed that the vitronectin binding
site is located on domains 2 and 3 of uPAR. However, Kanse
et al. [14] found that antibodies against domain 1 of uPAR
could block binding of uPA as well as vitronectin to endothe-
lial cells. This prompted us to study the interactions between
uPAR and vitronectin in more detail in a puri¢ed system
using real-time biomolecular interaction analysis. Our results
indicate that domain 1 of uPAR is required but not su⁄cient
for e⁄cient binding of vitronectin, in analogy with the mech-
anism demonstrated for uPA binding to uPAR [10].
2. Materials and methods
2.1. Proteins
Vitronectin was puri¢ed from human plasma according to a pub-
lished procedure [18]. Multimeric vitronectin was generated from the
plasma form by incubation in 6 M urea for 1 h at 37‡C followed by
extensive dialysis against PBS [19]. Glycolipid anchored uPAR and
uPAR(2+3) were puri¢ed by immunoa⁄nity chromatography of clari-
¢ed detergent phase fraction from Triton X-114 lysate of phorbol
12-myristate 13-acetate stimulated U937 cells by ¢rst retaining
uPAR on immobilized monoclonal antibody (Mab) R3 and
uPAR(2+3) on a R2 column as described previously [12]. Recombi-
nant soluble uPAR (suPAR) was puri¢ed from the conditioned media
of Chinese hamster ovary (CHO) cells transfected with a uPAR ex-
pression vector [20], with the only modi¢cation that immunoa⁄nity
puri¢cation was carried out using immobilized Mab R2 coupled to
CNBr-activated Sepharose 4B (Pharmacia LKB Biotechnology Inc.).
suPAR(2+3) and domain 1 were obtained by chymotrypsin (Wor-
thington Enzyme Corporation, Freehold, NJ) cleavage of suPAR fol-
lowed by puri¢cation by gel ¢ltration [9]. uPA was purchased from
Serono (Aubonne, Switzerland) and inactivated by treatment with
diisopropyl £uorophosphate (DFP) [21]. Recombinant, active PAI-1
was a kind gift from Dr. T.M. Reilly (DuPont Merck, DW). Both
forms of vitronectin and DFP-uPA were biotinylated according to
published procedures [22]. Plasma vitronectin and suPAR were iodi-
nated using the Iodogen procedure [10].
2.2. Antibodies
Monoclonal antibodies to uPAR were obtained from a fusion
where the mouse had been injected with uPAR puri¢ed from cell
lysates of phorbol ester stimulated U937 cells [23]. The antibodies
R2, R4 and R8 bind to epitopes on domain 2 or 3 of uPAR, whereas
R3, R5 and R9 bind di¡erent epitopes on domain 1 [20,23,24].
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2.3. Ligand-blotting analysis and Western blotting
Protein samples were separated by SDS-PAGE [25] and electroblot-
ted onto polyvinylidene di£uoride (PVDF) membranes. Ligand-blot-
ting was performed using 10 nM biotinylated DFP-uPA or 10 nM
biotinylated multimeric vitronectin (calculated average number of
monomeric vitronectin molecules per multimer = 4) using previously
described procedures [26]. Western blotting [23] was performed using
10 Wg/ml of R2.
2.4. Real-time biomolecular interaction analysis
All measurements were done employing the BIAcore 2000 instru-
ment (BIACORE, Uppsala, Sweden). Rabbit anti-mouse antibody
(RAM FcQ, BIACORE) was immobilized on the sensor chip CM 5
(BIACORE) at a concentration of 30 Wg/ml using the amine coupling
method according to the procedure provided by the manufacturer.
For immobilization of suPAR, the protein was pre-treated with neur-
aminidase for removal of sialic acids, since immobilization of non-
treated suPAR (pI 4.8 [8]) was found to be very ine⁄cient. The neur-
aminidase treated suPAR was immobilized on the sensor chip in the
same way as RAM FcQ. In single-layer experiments DFP-uPA or
vitronectin, in combinations with or without suPAR or suPAR frag-
ments, were used for injection. In multi-layer experiments, anti-uPAR
Mabs were bound to the RAM FcQ capturing molecules. Then suPAR
or suPAR(2+3) was added and interaction was measured after adding
varying concentrations of vitronectin. In some experiments uPA or
PAI-1 was included. The eluent in single-layer experiments was 10 mM
glycine-HCl pH 1.0 and in multi-layer experiments 1 M formic acid.
Calculations of kinetic constants were attempted using the BIAeval-
uation 2.1 software. The validity of the calculated data was assessed
using derived logarithmic plots as described [27]. Since the association
and dissociation rates measured in a multi-layer experiment are de-
pendent on the dissociation rate of several components, separate
curves were recorded with bu¡er as the last component of the mul-
ti-layer and these curves were subtracted from the curves obtained
with the varying vitronectin concentrations.
2.5. Immunoprecipitation
suPAR (2 nM or 5 nM) was incubated for 1 h at 4‡C with
125I-labeled plasma vitronectin (0.5 nM or 1 nM) in 0.1 M Tris-HCl
pH 8.1, 0.3 M NaCl, 0.1% Chaps (binding bu¡er) in a ¢nal volume of
15 Wl. Subsequently, 185 Wl binding bu¡er was added prior to further
incubation with 2 Wg of the Mab R2 for 1 h at 4‡C. Finally, 50 Wl of a
1:1 slurry of Protein A-Sepharose in binding bu¡er was added and the
samples were end-over mixed for an additional hour at 4‡C, after
which Sepharose was pelleted by centrifugation and the supernatant
withdrawn. The pellet was washed 6 times in binding bu¡er contain-
ing 0.1% (w/v) of bovine serum albumin, Sepharose being transferred
to new tubes during the washing procedure. The Sepharose pellets
were boiled in sample bu¡er, the supernatants analyzed by SDS-
PAGE [25] with detection of radio-labeled bands by autoradiography.
3. Results
3.1. The intact three-domain structure of uPAR is essential for
binding to vitronectin
Since the binding site for vitronectin on uPAR has been
claimed to reside in domains 2 and/or 3 [13], we wanted to
investigate if the cleaved form of uPAR, uPAR(2+3), could
bind vitronectin. Therefore, uPAR and uPAR(2+3), puri¢ed
from lysates of phorbol ester stimulated U937 cells, were
probed with either biotinylated multimeric vitronectin or
DFP-uPA in ligand-blotting assays (Fig. 1). Both ligands
showed binding to intact uPAR only (Fig. 1, lanes 1, 2 and
5), indicating the requirement for domain 1 of uPAR to ob-
tain vitronectin binding, as has previously been shown for
uPA binding to uPAR [7,9,10].
In order to study structural aspects of the interaction be-
tween uPAR and vitronectin we employed real-time biomo-
lecular interaction analysis. In these studies recombinant solu-
ble uPAR (suPAR) [20] and chymotryptic fragments thereof
[7] had to be employed in order to obtain su⁄cient amount of
puri¢ed protein and fragments (see also Section 4). To ensure
a uniform orientation of the molecule, suPAR was captured
on the sensor chip by various Mabs. The panel of anti-uPAR
Mabs employed included the domain 1 speci¢c R3, R5 and
R9, as well as R2, R4 and R8 recognizing epitopes on domain
2 or 3 [20,23,24]. suPAR captured by R2, R4 or R8 all bound
signi¢cant amounts of vitronectin, whereas no binding was
observed with suPAR captured by R3, R5 or R9 (Table 1).
These ¢ndings showed that immobilization of suPAR via do-
main 1 prevented the binding of vitronectin, possibly due to
competition between vitronectin and the respective antibody.
In the subsequent experiments Mab R2, giving the highest
signal with vitronectin (Table 1), was chosen for anchoring of
suPAR. The binding of vitronectin to intact suPAR as well as
to the chymotryptic cleavage product suPAR(2+3), was inves-
tigated (Fig. 2A and B). While intact suPAR bound both
plasma and multimeric forms of vitronectin, suPAR(2+3)
bound very little if any vitronectin, in accordance with the
result found above with glycolipid anchored uPAR.
Domain 1 is likewise known to be an essential element in
the binding of uPAR to uPA [7], but it has recently been
shown that the integrity of the multi-domain structure of
uPAR is required for high a⁄nity binding to uPA [9,10]. In
order to investigate whether vitronectin binding to suPAR
had similar characteristics, a Biacore-based competition assay
was designed, where either intact suPAR, suPAR(2+3) or do-
main 1 was allowed to interact with vitronectin prior to pas-
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Fig. 1. Ligand-blotting with multimeric vitronectin or DFP-uPA.
Immunoa⁄nity puri¢ed uPAR (lanes 1, 5, 7, V50 ng and lane 2,
V75 ng) and immunoa⁄nity puri¢ed uPAR(2+3) (lanes 3, 6, 8,
V50 ng and lane 4, V75 ng) were separated by SDS-PAGE and
blotted onto PVDF membranes. The samples in lanes 1 to 4 were
probed with biotinylated multimeric vitronectin (10 nM) and in
lanes 5 and 6 with biotinylated DFP-uPA (10 nM). Lanes 7 and 8
show Western blot with 10 Wg/ml Mab R2. The arrows indicate the
position of cell surface-bound uPAR and uPAR(2+3). The faint
band seen in lane 5 represents intracellular uPAR (Mr 43 000)
present in lysates from phorbol ester-stimulated U937 cells [5]. Elec-
trophoretic mobility of standard proteins are indicated to the right.
Table 1
Interaction between suPAR and vitronectin using anti-uPAR anti-
bodies as capturing molecules
Capturing Mab First analyte Second analyte
333 nM Mab (RU) 200 nM suPAR (RU) 200 nM VN (RU)
R2 2418.7 908.5 203
R3 1406.1 238.4 316
R4 1996.2 773.6 121
R5 1628.5 557.9 3136
R8 1307.5 548.6 92
R9 1198.9 295.8 384
RU values for analytes were corrected for non-speci¢c binding but not
for the variable dissociation of suPAR from the di¡erent Mabs.
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sage through a £ow cell with immobilized intact suPAR. For
this particular experiment the antibody capture assay could
not be employed, since both suPAR and suPAR(2+3), added
to the injected vitronectin, would bind any unoccupied bind-
ing sites on Mab R2. Therefore, suPAR had to be immobi-
lized directly on the sensor chip. For technical reasons (see
Section 2) this required desialylation of suPAR prior to im-
mobilization. However, it was ascertained that this modi¢ca-
tion of suPAR still allowed binding of both vitronectin and
uPA. In both cases the binding was competed e⁄ciently by
pre-mixing the injected protein with unmodi¢ed suPAR (Fig.
3). Only the intact suPAR prevented the binding of vitronec-
tin to the immobilized suPAR, whereas concentrations as high
as 800 nM of either suPAR(2+3) or domain 1 had hardly any
e¡ect on vitronectin binding (Fig. 3A). Using this assay we
also con¢rmed that intact suPAR is required for high a⁄nity
uPA binding (Fig. 3B) [9,10].
3.2. E¡ect of occupancy of uPAR with uPA
Binding of uPA to uPAR has been reported to augment the
binding between uPAR and vitronectin [13,14]. Since our re-
sults show that uPAR domain 1 is essential for both vitronec-
tin and uPA binding, we wanted to study the quantitative
details of this simultaneous binding. Therefore, we performed
kinetic analysis of the interaction between vitronectin and
suPAR in the absence or presence of uPA. This revealed
that at any of the vitronectin concentrations used, more vi-
tronectin was bound to suPAR when occupied with uPA than
to suPAR alone (Fig. 4). This qualitative observation could
however not be interpreted in terms of a simple kinetic model.
Thus, no reasonable ¢t was obtained, when the binding curves
were ¢tted to a second order monovalent association model
and a ¢rst order dissociation model.
3.3. Both forms of plasma vitronectin bind suPAR
Plasma vitronectin is present as a mixture of the intact
protein (Mr 75 000) and a cleaved form (Mr 65 000) due to
a cleavage site C-terminal to the heparin binding domain. In
order to study the complex formation between suPAR and the
individual forms of vitronectin, 125I-labeled vitronectin was
mixed with unlabeled suPAR in solution, followed by precip-
itation with Mab R2, which was also the capturing antibody
in the real-time biomolecular interaction analyses. It was as-
certained that vitronectin could be precipitated with Mab R2
only when suPAR was present (Fig. 5, lanes 1 and 2). The
electrophoretic pattern of precipitated, radio-labeled vitronec-
tin was indistinguishable from that obtained with a polyclonal
anti-vitronectin antibody (Fig. 5, lane 5). Thus, suPAR com-
plex formation occurred with both intact and cleaved vitro-
nectin.
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Fig. 2. Real-time measurement of interactions between vitronectin and suPAR or suPAR(2+3). suPAR (A) or suPAR(2+3) (B) were anchored
on a sensor chip using Mab R2 as the capturing molecule. The arrow A indicates start of injection of 333 nM R2 and B is R2 injection stop,
arrows C and D indicate start and stop, respectively, of injection of 100 nM suPAR (A) or 100 nM suPAR(2+3) (B) and arrows E and F indi-
cate start and stop of injection of 200 nM (15 Wg/ml) plasma vitronectin or 15 Wg/ml multimeric vitronectin. The £ow rate was 10 Wl/min. Each
injection lasted for 3 min after which the chip was £ushed with bu¡er to allow dissociation for 3 min.
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3.4. PAI-1 inhibits suPAR binding to vitronectin
PAI-1 binds with high a⁄nity to the amino-terminal region
of vitronectin [28,29]. To quantitate the e¡ect of PAI-1 on the
interaction between suPAR and vitronectin, increasing con-
centrations of active PAI-1 were pre-incubated with vitronec-
tin prior to passage through a £ow cell with Mab anchored
suPAR. The amount of bound vitronectin was found to de-
crease as a function of increasing doses of PAI-1 (Fig. 6). The
inhibition was maximal at equimolar concentrations of vitro-
nectin and PAI-1.
4. Discussion
The demonstration of an interaction between uPAR and
vitronectin [13,14] is particularly interesting because of the
potential function of uPAR as an adhesion protein in addition
to its role in governing cell surface proteolysis. The results
presented in this report elucidate a number of structural as-
pects of this interaction. We have demonstrated that domain 1
of uPAR is an essential part of the molecule in binding to
vitronectin, but that the intact receptor is indeed required for
e⁄cient binding, since domain 1 alone will not compete with
suPAR for binding to vitronectin (Fig. 3). The importance of
this observation is emphasized by the fact that in vivo uPAR
is cleaved on the cell surface [11,12]. Ligand-blotting experi-
ments with glycolipid anchored uPAR(2+3) revealed the com-
plete lack of binding of vitronectin, whereas vitronectin bound
to full length uPAR (Fig. 1). The real-time biomolecular in-
teraction analysis of vitronectin binding was done with re-
combinant suPAR and chymotryptic fragments, i.e. after
cleavage of uPAR between Tyr87 and Ser88 [7]. The
uPAR(2+3) puri¢ed from U937 cells arise from cleavage at
very close positions in the linker region between domains 1
and 2 and actually is a mixture of molecules with N-terminal
amino acids Ala84 or Ser90. The same cleavage sites are ob-
tained by incubation with uPA [12]. In our Biacore studies,
uPA treatment of suPAR would in£uence the subsequent
binding studies (Fig. 4). However, studies with the chymotryp-
tic fragment, suPAR(2+3) were in complete accordance with
the ligand-blotting results found with uPAR(2+3) from U937
cells. Thus, the results strongly suggest that uPA-catalyzed
uPAR cleavage on the cell surface prevents both vitronectin
and uPA binding.
Con£icting results have previously been reported concern-
ing the localization of the vitronectin binding site on uPAR
[13,14]. Our observation in real-time biomolecular interaction
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Fig. 3. Competition studies on suPAR vitronectin binding. Neuraminidase treated suPAR (30 Wg/ml) was immobilized using 10 mM sodium
acetate bu¡er, pH 5.0. In A the injected protein was 100 nM vitronectin alone (control) or mixed with 800 nM of either domain 1, su-
PAR(2+3) or intact suPAR. In B the analyte was 25 nM DFP-uPA alone (control) or mixed with 200 nM of either domain 1, suPAR(2+3) or
intact suPAR. The £ow rate was 10 Wl/min and the injection was stopped after 3.5 min after which the chip was £ushed with bu¡er to allow
dissociation for 2.5 min.
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analyses, that anchoring suPAR with any of the domain 1
speci¢c antibodies prevented vitronectin interaction, is in
agreement with studies of uPAR on endothelial cells in which
pre-incubation with domain 1 speci¢c antibodies prevented
both uPA and vitronectin binding [14]. This is in contrast to
another study, where Mab R4 (directed against domain 2+3)
was found to displace suPAR from vitronectin, whereas an
antibody to domain 1 showed no e¡ect [13]. Even though
di¡erent experimental conditions were used in the two studies,
the background for this discrepancy is not clear. Our study
clearly showed that the antibodies directed against domains 2
and 3, speci¢cally including Mab R4, could be used for an-
choring of suPAR to allow subsequent binding of vitronectin.
Along this line it was reported that partially puri¢ed su-
PAR(2+3) inhibited binding of uPAR to vitronectin, whereas
puri¢ed domain 1 had no e¡ect, leading to the proposal that
determinants within domains 2 and 3 were exclusively respon-
sible for binding [13]. However, the preparation of su-
PAR(2+3) employed in those studies was reported to be
90% pure [13] and could therefore contain intact suPAR in
su⁄cient amounts to explain the inhibition observed. Thus,
the observations as such are in complete accordance with our
¢ndings.
Our ¢nding that domain 1 is involved in interactions with
both uPA and vitronectin prompted us to study the mutual
in£uence of these two ligands on the binding process. We
found that simultaneous binding of uPA and vitronectin is
indeed possible as reported previously [13^16]. Furthermore,
we con¢rmed in a qualitative manner that binding of uPA to
suPAR increases suPAR’s capacity to bind vitronectin (Fig.
4). However, in the curve ¢tting analysis [30,31] simple kinetic
models for bimolecular reactions failed to ¢t the experimental
data. Thus, the present binding did not allow the assignment
of kinetic constants, even when correcting for the individual
FEBS 19639 17-12-97
Fig. 4. E¡ect of uPA on the interaction between suPAR and vitronectin. suPAR (100 nM, 575 RU immobilized) was captured on Mab R2
(200 nM) as in Fig. 1. In B 100 nM uPA (674 RU) was subsequently bound to suPAR. The ¢gure shows the curves obtained in the ¢nal injec-
tion step where increasing amounts of vitronectin (12.5 nM, 25 nM, 50 nM, 100 nM and 200 nM) was added at a £ow rate of 10 Wl/min.
Fig. 5. Immunoprecipitation of suPAR-vitronectin complexes. Puri-
¢ed preparations of suPAR and 125I-vitronectin (¢nal concentrations
indicated) were mixed and subjected to immunoprecipitation. The
precipitated proteins were analyzed by SDS-PAGE on a 6^16% gra-
dient gel under non-reducing conditions and autoradiography. Lane
1: suPAR (2 nM) mixed with 125I-vitronectin (0.5 nM) was precipi-
tated with 2 Wg R2. Lane 2: suPAR (5 nM) mixed with 125I-vitro-
nectin (1 nM) was precipitated with 2 Wg R2. Lane 3: 125I-vitronec-
tin (0.5 nM) was precipitated with 2 Wg R2. Lane 4: 125I-vitronectin
(0.5 nM) was precipitated with 10 Wg polyclonal antibody to vitro-
nectin. Lane 5: 125I-suPAR (1 nM, Mr 43 000) was precipitated with
2 Wg R2. The arrows indicate A: vitronectin dimers, B: intact vitro-
nectin monomer (Mr 75 000) and C: cleaved vitronectin monomer
(Mr 65 000).
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dissociation of the antigen-antibody complex and the uPA-
suPAR complex, respectively. Therefore, the resulting binding
situation may not be a simple equilibrium between a single
type of complex and two well-de¢ned reaction partners as
suggested previously [13], but rather a more complex situa-
tion, which is also indicated by a recent report showing that
di¡erent parts of the vitronectin molecule interacts with
uPAR [17].
As PAI-1 binds to vitronectin, it was in addition important
to study the in£uence of PAI-1 on the present molecular en-
semble. Since complex formation with PAI-1 was found to
prevent uPAR binding, uPAR and PAI-1 binding sites on
vitronectin are likely to be localized in close proximity. While
this manuscript was under preparation, Deng and co-workers
showed that both uPAR and PAI-1 bound to the amino-ter-
minal portion of vitronectin [16], in agreement with our com-
petition data. However, also the carboxy-terminal end of vi-
tronectin was recently shown to be important for uPAR
interactions [17], since peptides spanning residues 364^380 of
vitronectin, between the plasmin cleavage site after Arg361 [32]
and the endogenous cleavage site after Arg379, blocked bind-
ing of uPAR to vitronectin.
A complex pattern of interactions is emerging between
uPA, uPAR, PAI-1 and vitronectin, that apparently serves
to modulate cell-matrix interactions. uPA interacts with
uPAR through its growth factor domain and PAI-1 inacti-
vates uPA protease activity, thereby balancing pericellular
proteolysis. Independent of their enzymatic and inhibitory
activities, both uPA and active PAI-1 serve to modulate the
physical binding of uPAR to vitronectin [14,16,17]. uPA and
vitronectin bind to distinct areas of uPAR, in both cases re-
quiring the intact receptor for e⁄cient binding, whereas PAI-1
and uPAR recognize adjacent/overlapping sites on vitronectin.
Upon uPA-catalyzed cleavage of uPAR, liberating domain 1
[11,12], this complex system of protein interactions falls apart.
Interestingly, the remaining uPAR(2+3) is present on the cell
surface of many neoplastic cell lines [11,33^35]. It remains to
be investigated whether the recently reported complexes of
uPAR with L1-integrin [15] are dependent on the described
ligand interactions and whether cleaved uPAR is involved in
these interactions.
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